Merck Says Organon To Acquire Alydia Health
30 March 2021 - 11:20PM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. said that after the intended Merck spinoff
of Organon, Organon will acquire Alydia Health.
Alydia Health is a commercial-stage medical device company
focused on preventing maternal morbidity and mortality caused by
postpartum hemorrhage or abnormal postpartum uterine bleeding.
Organon will be a global healthcare company formed through a
spinoff from Merck to focus on women's health.
Organon agreed to acquire Alydia Health for up to $240 million
total consideration, including $215 million upfront plus a $25
million contingent milestone payment.
Of the upfront payment, $50 million will be paid prior to the
spinoff of Organon, $165 million will be paid by Organon upon the
close of the acquisition, and the remainder will be paid by Organon
upon achievement of the milestone.
Closing will be subject to completion of the spinoff of Organon
from Merck, currently anticipated late in the second quarter of
2021.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 30, 2021 08:05 ET (12:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024
